BIONTECH SE (NASDAQ: BNTX) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioNTech SE
January 22, 2024 06:00 ET
|
Bernstein Liebhard LLP
Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioNTech SE
ROSEN, LEADING TRIAL ATTORNEYS, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BNTX
January 21, 2024 20:15 ET
|
The Rosen Law Firm PA
NEW YORK, Jan. 21, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of BioNTech...
BIONTECH ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against BioNTech SE and Encourages Investors to Contact the Firm
January 17, 2024 21:00 ET
|
Bragar Eagel & Squire
NEW YORK, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against...
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BNTX
January 17, 2024 17:32 ET
|
The Rosen Law Firm PA
NEW YORK, Jan. 17, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of BioNTech...
BIONTECH SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioNTech To Contact Him Directly To Discuss Their Options
January 17, 2024 11:30 ET
|
Faruqi & Faruqi LLP
If you suffered losses exceeding $100,000 investing in BioNTech stock or options between March 30, 2022 and October 13, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi...
BIONTECH SE SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against BioNTech SE (NASDAQ: BNTX)
January 16, 2024 13:30 ET
|
Bernstein Liebhard LLP
Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against BioNTech SE (NASDAQ: BNTX)
BioNTech stellt strategische Prioritäten für 2024 auf der 42. jährlichen J.P. Morgan Healthcare-Konferenz vor
January 09, 2024 06:45 ET
|
BioNTech SE
BioNTech rechnet mit zehn oder mehr laufenden potenziell zulassungsrelevanten Studien bis Ende 2024Der Aufbau kommerzieller Kapazitäten zur Vorbereitung auf Produkteinführungen soll Ende 2025...
BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
January 09, 2024 06:45 ET
|
BioNTech SE
Plans to have ten or more potentially registrational trials by the end of 2024 Preparing to be commercial-ready by the end of 2025 Ended 2023 with approximately €17.5 billion (unaudited) in cash, cash...
BioNTech und DualityBio erhalten Breakthrough-Therapy-Status der FDA für ADC-Kandidaten BNT323/DB-1303 zur Behandlung von Gebärmutterkrebs
December 21, 2023 08:00 ET
|
BioNTech SE
Breakthrough-Therapy-Status basiert auf Phase-1/2-Daten zur Sicherheit und Wirksamkeit in Patientinnen mit Human Epidermal Growth Factor Receptor 2 („HER2“) -exprimierendem, fortgeschrittenen...
BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer
December 21, 2023 08:00 ET
|
BioNTech SE
Designation is based on Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing advanced endometrial cancer with encouraging early signs of...